Resting-state gamma-band power alterations in schizophrenia reveal E/I-balance abnormalities across illness-stages

Tineke Grent-‘t-Jong, Joachim Groß, Jozien Goense, Michael Wibral, Ruchika Gajwani, Andrew Gumley, Stephen M. Lawrie, Matthias Schwannauer, Frauke Schultze‐Lutter, Tobias Navarro Schröder, Dagmar Koethe, F. Markus Leweke, Wolf Singer, Peter J. UhlhaaseLife 2018 · DOI

TL;DR

This study uses MEG and MRS to investigate the excitation/inhibition (E/I) balance in schizophrenia (ScZ) across different illness stages. They found that early-stage psychosis (clinical high-risk, CHR) is associated with increased gamma-band power and a shift towards excitation, while later stages (first-episode and chronic ScZ) show reduced gamma-band power, suggesting a dynamic progression of E/I imbalance.

What Problem Does This Paper Address?

Schizophrenia (ScZ) is a complex mental disorder with a suspected underlying disruption in the balance between excitatory and inhibitory neural processes (E/I balance). While this E/I imbalance has been implicated in the pathophysiology of ScZ, it's unclear when these alterations emerge during the course of the illness and how they relate to clinical symptoms and cognitive deficits. Previous research has hinted at E/I disruptions, but direct physiological evidence across different illness stages using advanced neuroimaging techniques has been limited. This study aims to fill this gap by examining resting-state brain activity and neurochemistry in individuals at clinical high-risk (CHR) for psychosis, those in their first episode (FEP), and those with chronic ScZ.

Methods

The researchers employed two key neuroimaging techniques:

  • Magnetoencephalography (MEG): This non-invasive technique measures magnetic fields produced by electrical activity in the brain. They used MEG to record resting-state brain activity and applied a Dynamic Imaging of Coherence Sources (DICS) beamforming approach for source reconstruction. This allowed them to pinpoint the location of gamma-band activity (specifically in the 30-46 Hz and 64-90 Hz ranges) within the brain with high spatial resolution.
  • Magnetic Resonance Spectroscopy (MRS): This technique measures the concentration of specific neurochemicals in the brain. They used MEGAPRESS MR-Spectroscopy to quantify levels of GABA (gamma-aminobutyric acid, an inhibitory neurotransmitter) and Glx (glutamate/glutamine, excitatory neurotransmitters) in the right middle occipital gyrus. This allowed them to assess the E/I balance at a neurochemical level.

The MEG data was then correlated with neuropsychological scores (using the Brief Assessment of Cognition in Schizophrenia, BACS) and clinical symptom severity (using the Positive and Negative Syndrome Scale, PANSS, and the Comprehensive Assessment of At Risk Mental States, CAARMS).

Datasets

The study utilized data from several participant groups:

  • Clinical High-Risk (CHR) group: 88 individuals meeting criteria for early psychosis risk.
  • First-Episode Psychosis (FEP) group: 21 patients experiencing their first episode of psychosis.
  • Chronic Schizophrenia (ScZ) group: 34 patients with long-standing schizophrenia.
  • Control groups (CON1 and CON2): Matched control participants for each clinical group.

MRS data was collected from the CHR group (n=69) and their matched controls (CON1, n=35).

Key Insights and Ideas

  • Dynamic E/I imbalance across illness stages: The most striking finding is that the pattern of gamma-band activity changes significantly as schizophrenia progresses. This suggests that E/I balance is not a static deficit but rather a dynamic process that evolves over time.
  • Early psychosis as a "risk" state: Increased gamma-band power in the CHR group points to a state of heightened excitation, potentially reflecting a vulnerability or "risk" for developing psychosis. This is supported by the MRS data showing an elevated Glx/GABA ratio in this group.
  • Later stages involve reduced excitation: In contrast, FEP and chronic ScZ patients show reduced gamma-band power, suggesting a shift away from the initial hyper-excitability towards a state of reduced neural activity or altered network function.
  • Gamma-band power as a biomarker: The study proposes that resting-state gamma-band power, particularly the high-frequency range (64-90 Hz), could serve as a spectral fingerprint for psychosis risk and potentially for predicting illness progression.
  • Neurochemical underpinnings: The correlation between increased occipital gamma-band power and elevated Glx/GABA ratios in the CHR group provides a crucial link between neurochemical imbalances and electrophysiological markers of E/I disruption.

Key Results

  • CHR group: Showed increased high gamma-band (64-90 Hz) power in frontal and posterior-occipital regions. MRS data revealed significantly higher Glx concentrations and an increased Glx/GABA ratio in the right middle occipital gyrus compared to controls.
  • FEP and Chronic ScZ groups: Exhibited aberrant spectral power across both low (30-46 Hz) and high (64-90 Hz) gamma bands. Specifically, FEP patients showed decreased prefrontal low gamma-band activity and increased occipital activity, while chronic ScZ patients showed widespread decreased low gamma-band activity in frontal, temporal, and sensorimotor areas.
  • Correlations:
    • In the CHR group, increased gamma-band activity correlated with neurocognitive deficits and elevated psychotic symptoms.
  • In FEP and chronic ScZ groups, reduced gamma-band activity correlated with neurocognitive deficits and clinical symptoms.
  • Increased Glx and Glx/GABA ratio in CHR participants correlated significantly with increased occipital gamma-band power.

Limitations and Future Work

The authors acknowledge several limitations:

  • Cross-sectional design: The study's conclusions are based on a snapshot in time. Longitudinal studies are needed to confirm whether increased resting-state gamma-band power in CHR populations predicts clinical outcomes.
  • Age and sex differences: While efforts were made to control for these factors, differences in age and sex composition across groups were noted.
  • Medication effects: While most CHR and FEP participants were not on antipsychotic medication, the potential influence of medication on gamma-band power in chronic ScZ patients remains a consideration.
  • Static vs. dynamic analysis: The study focused on resting-state activity, and future research could explore dynamic aspects of brain networks, such as micro-states, to gain further insights.

The authors suggest that future studies should investigate the potential of resting-state gamma-band power as a biomarker for predicting psychosis onset and treatment outcomes. They also propose exploring dynamic network analyses to better understand the evolving nature of E/I balance in schizophrenia.

Summary updated

Abstract

We examined alterations in E/I-balance in schizophrenia (ScZ) through measurements of resting-state gamma-band activity in participants meeting clinical high-risk (CHR) criteria (n = 88), 21 first episode (FEP) patients and 34 chronic ScZ-patients. Furthermore, MRS-data were obtained in CHR-participants and matched controls. Magnetoencephalographic (MEG) resting-state activity was examined at source level and MEG-data were correlated with neuropsychological scores and clinical symptoms. CHR-participants were characterized by increased 64-90 Hz power. In contrast, FEP- and ScZ-patients showed aberrant spectral power at both low- and high gamma-band frequencies. MRS-data showed a shift in E/I-balance toward increased excitation in CHR-participants, which correlated with increased occipital gamma-band power. Finally, neuropsychological deficits and clinical symptoms in FEP and ScZ-patients were correlated with reduced gamma band-activity, while elevated psychotic symptoms in the CHR group showed the opposite relationship. The current study suggests that resting-state gamma-band power and altered Glx/GABA ratio indicate changes in E/I-balance parameters across illness stages in ScZ.
BibTeX
@inproceedings{grenttjong2018resting,
  author = {Tineke Grent-‘t-Jong and Joachim Groß and Jozien Goense and Michael Wibral and Ruchika Gajwani and Andrew Gumley and Stephen M. Lawrie and Matthias Schwannauer and Frauke Schultze‐Lutter and Tobias Navarro Schröder and Dagmar Koethe and F. Markus Leweke and Wolf Singer and Peter J. Uhlhaas},
  title = {{Resting-state gamma-band power alterations in schizophrenia reveal E/I-balance abnormalities across illness-stages}},
  booktitle = {eLife},
  year = {2018},
  doi = {10.7554/elife.37799},
}
Figure